A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: [14C]MK-8527

Study type: Interventional

Funder types: Industry

Identifiers

NCT06826989

8527-013

MK-8527-013 (Other Identifier)

Details and patient eligibility

About

The goal of this study is to learn how [14C]MK-8527 moves through a healthy person's body over time. Researchers will study how [14C]MK-8527 is absorbed by the body, broken down by the body, and how it leaves the body.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Is in good health
• Has a body mass index (BMI) of 18 to 32 kg/m^2

Exclusion criteria

• Has a history of cancer
• Has positive tests for hepatitis B surface antigen, hepatitis C antibodies or human immunodeficiency virus

Trial design

Primary purpose: Basic Science

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

[14C]MK-8527

Experimental group

Description:

Participants will receive a single oral dose of \[14C\]MK-8527 on Day 1

Treatment:

Drug: [14C]MK-8527